Surveillance of medication use in pregnancy is essential to identify associations between first trimester medications and congenital anomalies (CAs). Medications in the same Anatomical Therapeutic Chemical classes may have similar effects. We aimed to use this information to improve the detection of potential teratogens in CA surveillance data.
Introduction
The first trimester of pregnancy is an essential stage of development for the fetus, when organs undergo critical steps in their development and most noninherited congenital anomalies (CAs) occur. Certain medications can cause CAs when taken during early pregnancy, yet exposure to prescription and over-the-counter medication during pregnancy is common [1, 2] . Despite this widespread use, information on the safety of medicines in human pregnancy is lacking, particularly for new products; a key reason is that pregnant women are usually exempt from premarketing medication safety studies. When a medication is licensed for marketing, little or nothing is generally known about the safety for its use during pregnancy. Whilst information about reproductive toxicity is sometimes available from animal studies, these are limited in their ability to predict risks of CA in humans [3] . As such, postmarketing studies and the continued surveillance of medication use in pregnancy are essential to detect new teratogens.
EUROmediCAT is a network of European CA registries, which has developed a systematic signal detection method to identify medications potentially associated with an increased risk of specific CAs [4, 5] . This method searches thousands of medication-CA combinations to identify a small set of medication-CA combinations that are more likely than the other combinations to contain some true associations between the medications and the CAs. These combinations are called signals and, once identified, they need to be investigated in detail [6] . To only identify a small set of signals, a false discovery rate (FDR) procedure is used. The FDR is the proportion of false positive results among the set of all positive results, e.g. an FDR of 10% means that up to 10% of identified associations are expected to be false positives. The Anatomical Therapeutic Chemical (ATC) system is used to code medications [6] , with those in the same ATC classes often working in similar ways. However, this information is not incorporated in the current EUROmediCAT signal detection method, which examines each medication and each CA separately [5] . In this study, we aimed to refine signal detection methods for CA data by using a double FDR procedure, which takes groupings of ATC medications or groupings of CA into account. If similar medications are likely to have similar teratogenic effects or if similar anomalies are likely to be caused by the same medications, then the double FDR will use this information, and may be a more efficient method to identify signals compared to the single FDR method. The double FDR was first proposed by Mehrotra and Heyse in 2004 [7] ; here we use an improved version of the double FDR as presented by Mehrotra and Adewale in 2012 [8] .
Methods

Study population
Built on the European Surveillance of Congenital Anomalies (EUROCAT) network of population-based CA registries, EUROmediCAT includes registries with information on first trimester medication use. Consistency of inclusion criteria, data collection and recording across EUROCAT registries is monitored using data quality indicators [9] . EUROmediCAT data on malformed fetuses with first trimester medication exposures from 1995-2011 were available, for a population coverage of around 7 million births from 11 European countries, across 13 registries that agreed to participate in this study (Table 1) . Ethical and data access approvals were obtained for each database from the relevant governance infrastructures. A large proportion of this EUROmediCAT dataset has been previously analysed for signal detection purposes [5] .
Congenital anomaly data
EUROCAT registries use multiple sources of information to ascertain all CA cases, including live birth, fetal death and termination of pregnancy for fetal anomaly. Data are obtained through active case finding and voluntary reporting [10] . All EUROCAT registries use a standardized methodology, i.e. standard variables, definitions and coding instructions [11] . CAs are coded according to EUROCAT coding guide version 1.4, which uses the International Classification of Diseases (ICD) version 10 with the British Paediatric Association (BPA) extension. ICD10-BPA codes are used to group cases of CA into standard subgroups, described in detail in the EUROCAT coding guide 1.4 (http://www.eurocat-network. eu/content/Section%203.3-%2027_Oct2016.pdf) [11] . Cases with genetic conditions (chromosomal anomalies, skeletal dysplasia, genetic syndromes or microdeletions) were excluded from this study. Fetuses with isolated congenital dislocation of the hip as their only major CA were also excluded, since the aetiology of this CA is mechanical. Fetuses exposed only to vitamins, minerals and/or folic acid were excluded. Fetuses with a congenital heart defect (CHD) but no Terminations of pregnancy for fetal anomaly were excluded from the Emilia Romagna registry as information on medications is only available for live and still birthsCA, congenital anomaly; ATC, Anatomical Therapeutic Chemical information regarding the specific type of CHD were combined into a separate subgroup (unspecified CHD, n = 542) for analysis purposes. We performed signal detection for 55 EUROCAT CA subgroups that were analysed in the previous EUROmediCAT signal detection analysis, but here including two fewer CAs due to a more recent version of EUROCAT coding being used for the extraction of data.
Exposure data
Maternal medication exposure data in EUROmediCAT are obtained from prospectively recorded maternity records (medical files); additional data sources include general practitioner records, maternal interviews and infant medical records [12, 13] . Data collection and processing methods vary, with completeness of information and the type of medications recorded (e.g. over-the-counter, prescribed use and/or actual use) differing between registries [12] . Inclusion in the EUROmediCAT database requires first trimester exposures, defined as the first day of a woman's last menstrual period to the end of her twelfth gestational week [11] . The EUROCAT coding guide instructs registries to calculate length of gestation by using "best estimate based on last menstrual period and/or ultrasound determination". An unlimited number of exposures are recorded using the hierarchical ATC system, with up to seven digits and free text information where required. Medications were analysed using seven-digit ATC5 codes; five-digit ATC4 level codes were used only where a more detailed ATC5 code was unavailable. We were not able to differentiate between exposures to the same medication at different dosages since EUROmediCAT registries do not routinely include this information. ATC codes subject to alterations over time were identified from the WHO website [14] , with older codes updated where available. Cases exposed exclusively to codes with fewer than five digits (not coded to at least ATC4), topical medications (including eye drops and other nonoral/non-IV medications) and medications taken in the 2 nd /3 rd trimester or with unknown timing were also excluded. Medications recorded in fewer than three fetuses were not investigated, but fetuses exposed to these medications were included as controls in analyses.
Statistical analysis
For each medication-CA combination, the proportion of CA cases in fetuses with the medication exposure was compared to the proportion of that CA in all other fetuses in the dataset (i.e. those without that specific medication but exposed to at least one other medication). An unadjusted, one-sided Fisher's exact test was used. For each medication-CA combination, registries with no exposures and registries with no cases were excluded from that particular analysis. Outcomes were reported using proportional reporting ratios and P-values. All analyses were performed using Stata version 12 [15] . A single Simes adjustment [16] across all medication-CA combinations was used to control the FDR, as per existing EUROmediCAT methodology [5] . We compared this to a double FDR procedure [8] , incorporating an additional step to consider groupings of medications.
The single FDR procedure is specified for m tests and an FDR cut-off α as follows
• Order P-values P i according to their magnitude P 1 < … < P m • Let e P i denote the FDR adjusted value for P i , where
• Null hypotheses with e P i ≤α are rejected; these combinations are the potential signals.
The double FDR is specified for i = 1, …, n medication groups each with g i ( j = 1, …, g i ) medications as follows.
Step 1: Perform a single FDR adjustment (as above) within each group i to get e P ij , then let P Ã i denote the smallest FDR-adjusted P-value in each group
Apply an FDR adjustment to the P Ã i to get the set of representative FDR-adjusted P-values e P Ã i , where
All groups i where e P Ã i ≤α are taken to the second step.
Step 2: Let F≡ P ij j e P is the FDR-adjusted P-value for all P ij ∈ F. Null hypotheses are rejected for all tests where e P F ð Þ ij ≤α; these combinations are the potential signals.
The FDR cut-off is defined for a prespecified proportion α between 0 and 1; e.g. α = 0.1 corresponds to an FDR of 10%, meaning that up to 10% of combinations identified as signals are expected to be false positives. The overall FDR level for double FDR is at most α at the group level no matter how many groups contain at least one true signal, hence it may be possible that the overall FDR exceeds α in some scenarios [8] . A lack of low powered associations violates the underlying assumptions of a multiple testing procedure by markedly shifting the distribution of P-values towards zero; associations for combinations with fewer than three exposed cases were therefore retained in the multiple testing procedures, but were not flagged as signals for further consideration.
Grouping of medication-anomaly combinations
Medications were grouped according to pharmacological subgroups using four-digit ATC3 codes (n = 116 groups). ATC4 (chemical subgroup) codes were considered too detailed for grouping purposes, resulting in a large number of groups (n = 244). ATC2 (therapeutic main group) levels would provide a smaller number of groups (n = 61), but these would include a range of medications and were considered too heterogeneous for grouping purposes. Both ATC2 and ATC4 were considered in sensitivity analysis. Certain CAs are thought to be more sensitive (compared to other types of CAs) to medications in general, and it may be likely that a number of CAs have no signals at all. We therefore also considered grouping medication-CA combinations by CA.
Evaluation and comparison of signal detection methods
The Australian Government Department of Health provides a database of recorded pregnancy related risks associated with medicines [17] . All medications are divided into five main lettered categories: category A medications are considered safe for use during pregnancy; category B have not shown evidence of harmful effects to human fetuses; category C may carry harmful effects to human fetuses, without evidence of causing CAs; categories D and X have evidence of moderate to high teratogenic risk. Specific CAs are not identified. This database was used to independently identify medications for which there has been evidence of high teratogenic risk by grouping medications as high-risk (categories D and X) or low-risk (categories A, B or C). Medications that could not be mapped to a risk category (i.e. that were not present) in this database were grouped as unclassified-risk. Medication names were matched to EUROmediCAT data using substance names. The total number of high-risk medications identified by single and double FDR were compared, and the proportion of all the high-risk medications in the data that were identified as signals was calculated. This was defined as
Identification rate
¼
Number of high-risk medications identified as signals Total number of high-risk medications in the data
The total number of medications in the set of signals (the effective workload), identified by each method was also considered, since each medication signal requires further investigation regardless of the number of different with which CAs it may be associated.
Results
Description of signal detection dataset
A total of 31 197 fetuses with at least one first trimester medication exposure and a major CA born from 1995 to 2011 were extracted from the EUROmediCAT central database for 13 registries. Of these, 905 fetuses with isolated congenital dislocation of the hip, 1219 with no ATC4 or ATC5 exposures recorded and 452 with only topical medication exposures were excluded, leaving 28 621 fetuses with valid medication exposures ( Table 1) . Fetuses with exposures only occurring outside the first trimester of pregnancy (n = 1490) or with unknown timing (n = 12 073) were further excluded, leaving 15 058 fetuses for analysis. Some registries had considerable data loss where it was not possible to verify when the reported medications had been taken (Table 1) , and this has been discussed previously [5] . However, the distribution of types of CA were similar for those pregnancies included and excluded due to unknown timing, suggesting that cases remaining in the dataset for these registries are not prone to selection biases in this respect. On average, there were 1.6 recorded ATC nontopical medication exposures per pregnancy, ranging from one (in 65% of cases) up to 16 (one case). The total number of exposures to medications appearing at least three times in the dataset was 22 624; this included 523 ATC medications, of which 39 (7.5%) were coded only to ATC4
Of the 523 medications in the data, 297 (57%) were lowrisk, 44 (8.4%) were high-risk and 182 (35%) had unclassifiedrisk according to the Australian risk categorization database. Three medications mapped to a code in both the low-risk and high-risk groups depending on their dosage. As there is no information on dosage in EUROmediCAT data, these medications were not assigned to either risk category but were instead coded as unclassified-risk. Of the 116 ATC3 groups, 94 (81%) contained no high-risk medications, 13 (11%) contained only one, and 9 (8%) groups contained two or more high-risk medications.
Comparison of single and double FDR procedures to adjust for multiple testing
There were no cases for 369 specific medication-CA combinations, hence Fisher's exact test was performed for 28 396 combinations. Figure 1 is a smileplot [18] of the proportional Figure 1 Smileplot highlighting signals identified from 28 396 medicationcongenital anomaly combinations by single and double false discovery rate (FDR) procedures, using a cut-off of 50% and ATC3 grouping (P-values truncated at 1.0E-10)
reporting ratios against the P-value for each combination. Without adjustment for multiple testing, 670 combinations were significant at the conventional 5% level (points above the lower dashed line in Figure 1 ). For a cut-off of 50%, single FDR resulted in 10 medication-CA combinations being identified as signals (diamond symbols in Figure 1 ), involving eight medications (one medication had signals for three CAs). Double FDR 50% resulted in 25 medication-CA combinations being identified as signals (+ symbols in Figure 1 ), involving 16 medications (four medications had signals for two CAs, one medication for three CAs and one medication for four CAs) in five ATC3 groups.
Double FDR 50% signals included five antiepileptic medications (four high-risk, one low-risk), four insulin medications (two low-risk, two unclassified-risk), three sex hormones (one high-risk, two unclassified-risk), two antiasthmatic medications (both low-risk), one unclassified-risk gynaecological medication and one high-risk medication for acid related disorders. Single FDR 50% identified only seven of these medication signals over 10 combinations, including two of the antiepileptics (both high-risk), two antiasthmatics (both lowrisk), one unclassified-risk insulin-related medication and one unclassified-risk sex hormone. Single FDR 50% also identified one further signal for a low-risk anxiolytic medication, which was not a signal using double FDR 50% and was in an ATC3 group including eight other medications that were not signals using either method. Figure 2 presents the number of signals in each risk category using ATC3 groupings for single and double FDR across a range of cut-offs from 5-50%. Higher cut-offs resulted in a greater number of signals being identified for both methods. Up to three high-risk signals were identified by single FDR for any cut-off from 15-50%. Only one additional low-risk medication was identified as a signal for an FDR cut-off of 35% and above. Six high-risk medications were identified by double FDR 30%, above which level only one further (low-risk) medication signal was identified. The proportion of signals that were high-risk was highest for double FDR at a cut-off of 10% or less; above this threshold the single and double FDR had similar proportions of high-risk signals. Figure 3 shows the identification rate for single and double FDR with cut-offs from 5-50%. Double FDR identified more of the high-risk medications than single FDR, for a range of FDR cut-offs and comparable effective workloads (the number of medications identified as signals).
Sensitivity analyses
FDR procedures were repeated using ATC2 and ATC4 codes and CAs to group medication-CA combinations. Grouping by ATC2 provided 61 groups with an average of 20 (range one to 54) medications per group. ATC4 gave 244 groups, with an average of three (range one to eight) medications per group. Both these groupings resulted in similar or lower effective workloads across the different levels of FDR cut-off; however, the number and proportion of high-risk medications detected was generally lower compared to ATC3 groupings. For FDR 25%, for example, ATC3 groupings identified a 11 medication signals of which five were high-risk, compared to 12 (five high-risk) and six (two high-risk) for ATC2 and ATC4 groupings, respectively. Grouping of medication-CA combinations by the 55 CAs an average of 518 (range 325-523) unique medication-CA combinations per group; this resulted in a greater number of signals across all levels of FDR cut-off, with no increase in the number of high-risk medications identified. This might be influenced by the use of a risk Figure 2 Effective workload and the number of medication signals in each risk category as identified by the Australian risk categorization system database for single and double false discovery rate (FDR), at FDR cut-offs ranging from 5% to 50%
Identifying harmful medications in pregnancy classification system to judge the methods, since these are not specific to the type of CA. Overall, however, grouping by ATC2, ATC4 or CA did not show an improvement over ATC3 grouping.
Of 523 medications in the analysis, 35% had unclassified-risk (not present in the Australian classification system database). Sensitivity analyses were conducted to assess the effect of a number of hypothetical situations. Firstly, medications without a risk category were assumed to either be all high-risk or all low-risk, representing the two most extreme situations. We also considered the effect of assuming that a medication with unclassified-risk was high-risk if there was at least one other high-risk medication in that group, and low-risk if all medications in the same group had lowor unclassified-risk. For these three situations, comparisons between single and double FDR were the same as described previously, and conclusions remained unchanged (data not shown).
Discussion
We compared two FDR procedures for use in EUROmediCAT's signal detection process to assess whether the FDR multiple testing adjustment could be improved by incorporating medication groupings. The double FDR identified more high-risk medications as signals than the currently used single FDR method, for a range of FDR cut-offs and comparable resulting workloads. Using double FDR, a cut-off level of 50% was judged appropriate, as it resulted in a reasonable effective workload (16 medication signals over 25 combinations) requiring follow up. The only medication that was a signal using single but not double FDR was in the low-risk category. All but one of the 16 additional signals from double FDR were in ATC3 groups including at least one other signal, highlighting how the double FDR picks up more signals in groups where there are other (stronger) signals.
Results were also compared to those from the previous EUROmediCAT signal detection analysis (using single FDR with a 50% cut-off [5] ), for which the dataset differed by omission of two registries and inclusion of an additional year of data for another two registries. Of the 26 combinations identified as signals in the present analysis, 20 were signals in the previous EUROmediCAT analysis. Combinations that were signals here but not in the previous analysis (where their FDR-adjusted P-values did not reach statistical significance using single FDR) included antiepileptic medications, which are well-established as being a teratogenic group of medications [19] [20] [21] , and progesterone sex hormones, which have been previously linked to an increased risk of hypospadias [22] and CHDs [23] . All signals identified in this study have been reported previously in the literature; however, as the EUROmediCAT database increases in size annually, future analyses are expected to identify new associations, particularly for newer medications. The identification of signals using double FDR is more powerful than single FDR methodology, and will provide additional independent information to confirm the results of hypothesis driven studies for specific types of medications, as well as evidence to perform new hypothesis driven studies.
Statistical considerations
The choice of FDR cut-off level should balance the proportion of false negative and false positive associations. If this is set too high, the resulting workload for follow up of associations may be impractical, and there is potential for unwarranted anxiety to pregnant women if false positive associations are reported. A low FDR cut-off, conversely, could miss important signals and result in delay of detecting such teratogens until more data (i.e. more exposures to harmful medications) are available. The FDR 50% used here might be considered a higher than acceptable rate of likely false positives, but when considering this in contrast to a lack of any adjustment for multiple testing (where the FDR approaches 100%), a cut-off of 50% is an improvement. The choice of FDR cut-off should be re-evaluated frequently, and in practice should depend on resources available for follow-up of signals. One-sided tests are used for CA signal detection as only fetuses with a CA are included; if a medication reduces the risk of a CA there will, by definition, be fewer cases in the study population and therefore a low power to detect preventive medications. Two combinations indicated preventive associations using both FDR procedures; these associations are probably due to chance or biases occurring from the study design (as controls all have at least one CA and one medication exposure). Furthermore, the comparison is to other CAs and medications in the database, hence preventive associations would not imply that the overall risk of a CA is likely to be lower. Adjustment for registry was not done as numbers were already small for the majority of combinations.
Figure 3
Proportion of high-risk medications in the EUROmediCAT signal detection dataset that were identified as signals (identification rate) against the total number of medication signals (effective workload) for single and double false discovery rates (FDRs), with each point corresponding to a level of FDR cut-off ranging from 5% to 50%
Evaluation of signal detection methods
Evaluation of signal detection methods in CA data is difficult due to the lack of a gold standard to classify risks for medications in pregnancy according to CAs. A definitive measure of how many teratogens are missed by a signal detection method, and possible reasons for such lack of detection, cannot therefore be obtained. To evaluate EUROmediCAT's signal detection process we used the Australian classification system to assign risk categories to medications. Two important limitations of this risk classification are pertinent here; firstly, there was no available classification of pregnancy-related risk for around a third of medications in the EUROmediCAT database. It might have been possible to garner further information on some of these unclassified medications by also using the Swedish and US risk classification systems, as done in a previous web-based study of medication safety of in Europe [24] . However, after including information from all three classification systems in their study, 23.2% of medications still remained unclassified [24] , indicating that only a relatively small improvement would be made by including additional information from these other databases. We therefore considered the use of one database sufficient for our main purpose of directly comparing the FDR methods. Secondly, an important limitation of these risk classification systems in general is that specific CAs are not identified for high-risk medications. However, the teratogenic risk of a medication is almost always specific to one (or more) particular CA(s), rather than an increased risk of malformations in general [25] . The identification rate used in this study does not differentiate between a medication associated with only one CA and one associated with a number of CAs.
Two of five low-risk signals identified using double FDR with a 50% cut-off were insulin medications. It is not surprising to find the insulin medications in the low risk category according to the Australian classification system because, although the association between insulin medications and CHDs is well documented, this is thought to be a result of the fact that the mother has diabetes rather than the insulin medications themselves [26] [27] [28] . This example of potential confounding by indication highlights that signal detection cannot distinguish between cause and effect, and emphasizes the importance of further evaluating signals from a medical and biological perspective. The number of combinations identified as high-risk may be overestimated, since categorizations are specific only to the medications and not the type of CA. Conversely, medications classified as B or C in the Australian database may be given their classification due to a lack of power with information available at the time of categorization, and as such we cannot definitively say that these medications are known to be low-risk. Due to these issues, the Australian categorization system is not as precise as would be ideal for use as a gold standard in classifying teratogenic risk. However, the aim of this study was to directly compare the single and double FDRs, and each procedure should have the same lack of data and power for known teratogens. We cannot provide an absolute measure of how good either method is for two main reasons. Firstly, there is a lack of a gold standard. Secondly, the number of women exposed to well-established teratogens (such as thalidomide or isotretinoin) during pregnancy is now very low due to their known risks; hence, the power to detect signals for such medications in more recent data is low. It is therefore important to adopt more efficient methods of signal detection than are currently being used, rather than delay adoption due to a lack of evidence based on relatively low overall detection rates across the methods.
Strengths and weaknesses
A major strength of EUROmediCAT data is the detailed and standardized coding of CAs across registries [13] , combined with detailed information regarding first trimester medication exposures. Good agreement between the medication actually used and that recorded in one EUROmediCAT registry has also been previously demonstrated [29] . Whilst there are variations across the registries in the way data regarding maternal medication use are collected, and in the quality and completeness of these data, there is no reason to believe that either the single FDR or the double FDR method will be more or less robust to such variations between registries. A potential weakness of EUROmediCAT data is known under ascertainment of some medications [12, 30] , which may reduce the sensitivity of signal detection analyses. Another important limitation is the lack of information regarding the dosage of medication exposures, which is particularly relevant as medications in different dosages can have different teratogenic effects. Timing of exposures could not be confirmed in a number of cases (a high proportion for the Polish registries), resulting in a loss of power and a source of potential bias. After data cleaning, all included cases were supposedly confirmed first trimester exposures; however, it is not possible to know that the mothers took the medication during the critical period for development of each specific CA, particularly since these can differ according to the type of CA [31] . In these analyses, the large number of statistical tests involving very small numbers of exposures prohibits accurate adjustment for potential confounders, therefore multiple comparisons procedures are performed on unadjusted results. Nonetheless, heterogeneity between registries is considered in the next stage of the signal detection process; the first EUROmediCAT signal detection analysis was published alongside an accompanying paper that evaluated identified signals in detail, considering, amongst other factors: heterogeneity between registries, registry-specific effects, and potential confounding by indication or by co-exposure [32] . An advantage of case-malformed control studies is that some biases associated with the use of a healthy control population (e.g. recall and recording biases) are likely to be minimized. By contrast, this type of study cannot produce medication exposure risk estimates for CAs compared to healthy (i.e. nonexposed and nonmalformed) controls [33] ; evidence of an increased risk of any CA in this study is relative only to the risks associated with other CAs.
Conclusion
The double FDR identified a greater number and proportion of high-risk medications as signals than the currently used single FDR, for a range of FDR cut-offs and comparable resulting workloads. We therefore recommend that double FDR be used in routine signal detection analyses of CA data. This
Identifying harmful medications in pregnancy may help identify potentially teratogenic medications that could be missed by the existing single FDR procedure, whilst retaining an acceptable level of false positive associations. Signal detection analyses of CA data must continue to be accompanied by detailed follow up of any new potential signals identified and timely dissemination of results; together, this will help patients make appropriate decisions to balance any risks and benefits of medication use during their pregnancy, based on the most up-to-date information available.
